# Peter Marks

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/peter-marks
Canonical HTML page: https://getyourbrief.com/entity/peter-marks

## Timeline

- **2026-03**: Final Departure — Official announcement of Marks leaving the agency for the second time.
- **2026-02-23**: Expedited Pathway Formalized — FDA announces the formal implementation of quicker paths for gene therapy via surrogate endpoints.
- **2025**: Initial Friction — Reports surface of Marks considering resignation amid administrative policy shifts.
- **2024-05-15**: START Pilot Launch — FDA initiates a pilot program for Support for clinical Trials Advancing Rare disease Therapeutics.
- **2023-03-01**: CBER Reorganization — The Office of Tissues and Advanced Therapies is elevated to a 'Super Office' to handle CGT volume.
- **2020**: Operation Warp Speed — Plays a central role in the emergency use authorizations for COVID-19 vaccines.
- **2017-12-19**: Luxturna Approval — FDA approves the first gene therapy for an inherited disease, setting the initial regulatory precedent.
- **2016**: Appointed Director — Promoted to Director of CBER, overseeing the 'Gold Standard' of vaccine review.
- **2012**: Joins FDA — Dr. Peter Marks joins the FDA as Deputy Director of CBER.

## Recent coverage (2 stories, network-wide)

### FDA Vaccine Chief Departs Amid Regulatory Overhaul and Political Pressure
2026-03-07 01:51:00 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 6

Dr. Peter Marks, the long-serving head of the FDA’s vaccine division, is stepping down for the second time as the Trump administration intensifies its 'Make America Healthy Again' initiatives. His exit marks a critical turning point for the Center for Biologics Evaluation and Research and signals a potential shift in the agency's rigorous approval standards.
Full story: https://gethealthbrief.com/story/fda-vaccine-chief-departure-trump-administration

### FDA Accelerates Gene Therapy Approvals via New Regulatory Framework
2026-02-23 22:35:23 · Sector: legal · Sentiment: Positive · Impact: 8/10 · Sources: 8

The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.
Full story: https://getlegalbrief.com/story/fda-expedited-gene-therapy-pathway

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.